Notifiche
Cancella tutti

Gadopentetate dimeglumine - Gd-DTPA

1 Post
1 Utenti
0 Reactions
0 Visualizzazioni
(@Utente 0002)
Registrato: 1 secondo fa
Post: 0
  [#1633]

Il Gadopentetate dimeglumine of 1-deoxy-1-(methylamino)-D-glucitol dihydrogen [N,N-bis[2-[bis(carboxymethyl)amino]ethyl] glycinato (5-) ]gadolinate(2-)(2:1) è una molecola utilizzata in risonanza magnetica come mezzo di contrasto positivo in T1.
E' un mezzo di contrasto ionico, ed è stato il primo ad essere introdotto sul mercato nel lontano 1980.
Coomercializzato come Magnevist dalla Bayer HealthCare Pharmaceuticals

Osmolality (mOsmol/kg water) at 37° C 1,960
Viscosity (CP) at 20° C 4.9
Density (g/mL) at 25° C 1.195
Specific Gravity at 25° C 1.208
Octanol: H2O Coefficient at 25° C, pH7 log Pow = - 5.4

[allegato non incluso]

La dose consigliata è di 0.1 mmol/kg ma può essere portata fino a 0.3 mmol/kg, con somministrazione a bolo.

Citazione
WARNING
NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

  • Do not administer OptiMARK™ (gadoversetamide injection) to patients with:

    • chronic, severe kidney disease (GFR < 30 mL/min/1.73m²), or
    • acute kidney injury (see CONTRAINDICATIONS).
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • Do not exceed the recommended OptiMARK™ (gadoversetamide injection) dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration (see WARNINGS).



   
Citazione
Condividi: